Results 1 to 10 of about 124,365 (347)

Proton-pump inhibitors [PDF]

South African Family Practice, 2015
Proton-pump inhibitors (PPIs) are a class of drugs that profoundly suppress gastric acid secretion, and thus have become the treatment of choice for gastro-oesophageal reflux disease and peptic ulcer disease. PPIs are considered safe and effective. It is
Vasudevan G. Naidoo
doaj   +5 more sources

Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study [PDF]

European Journal of Epidemiology, 2010
A case-control study comprising 1315 Campylobacter jejuni cases, 121 Campylobacter coli cases and 3409 frequency-matched controls was conducted in The Netherlands in 2002-2003. Risk factors for both C. jejuni and C.
Brandhof, W.E., van den, Breukink, B.J., Doorduyn, Y., Duynhoven, Y.T.H.P., van, Pelt, W., van, Wagenaar, J.A.   +5 more
core   +16 more sources

Hypocalcemia After Thyroidectomy in Patients Taking Proton Pump Inhibitors [PDF]

Laryngoscope Investigative Otolaryngology
Objective Calcium homeostasis is regulated by the effects of parathyroid hormone (PTH) and vitamin D on the bones, GI tract, and kidneys. Post‐thyroidectomy hypoparathyroidism and resultant hypocalcemia are common complications associated with prolonged ...
Maxwell Rossip, F. Jeffrey Lorenz, Neerav Goyal, David Goldenberg   +3 more
doaj   +2 more sources

Proton-pump inhibitors and risk of renal disease [PDF]

Journal of Nephropharmacology, 2017
Proton pump inhibitors (PPIs) are one group of drugs that inhibit gastric acid secretion by binding irreversibly to the gastric proton pump to the gastric proton pump.
Mahrang Hedaiaty, Mohammad Reza Tamadon, Armin Amiri, Leila Mahmoodnia   +3 more
doaj   +4 more sources

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
A Deshpande, A Liberati, A Niklasson, Abdur Rahman Khan, Abed AlLehibi, Alex J. Sutton, Aref A. Bin Abdulhak, AZ Mat Saad, BT Batuwitage, C Bavishi, C Cahir, CM Wilcox, CS Eom, CS Kwok, D Ahrens, DF Stroup, DL Bhatt, DO Lowe, F Sierra, Faisal A. Alasmari, GH Guyatt, Imad M. Tleyjeh, J Johnstone, J Leonard, J Theisen, J Thorens, J Zhang, JL Peters, JM Boyce, JS Bajaj, KH Wilson, Larry M. Baddour, LC McDonald, LK Archibald, M Charlot, M Egger, Markus M. Heimesaat, MD Howell, MD Redelings, MM Nerandzic, Mohamad Al Tannir, Muhammad Riaz, Musa A. Garbati, Mushabab AlGhamdi, Patricia J. Erwin, PK Kutty, PS Yachimski, R DerSimonian, R Scagliarini, RL Jump, S Dial, S Janarthanan, S Jayatilaka, S Linney, S Schneeweiss, SG Moreno, SG Moreno, Talal Ibrahim, WR Jarvis   +58 more
core   +14 more sources

Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients. [PDF]

PLoS ONE, 2015
To determine whether there is an association between overprescription of proton pump inhibitors (PPIs) and multimorbidities in older patients.Multicenter prospective study.Acute geriatric medicine at the University Hospital of Nantes and the Hospital of ...
Anne Delcher, Sylvie Hily, Anne Sophie Boureau, Guillaume Chapelet, Gilles Berrut, Laure de Decker   +5 more
doaj   +1 more source

Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study

Biomedicines, 2022
(1) Background: Hepatic encephalopathy (HE) is a common complication in cirrhosis patients, and recently, clinical evidence indicates that a higher risk of HE is associated with the usage of proton pump inhibitors.
Pan Zhang, Lizhi Zhou, Li Chen, Zhen Zhang, Rui Han, Gangwen Guo, Haocheng Zhou   +6 more
doaj   +1 more source

Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics

Frontiers in Pharmacology, 2020
BackgroundDue to their efficacy and tolerability, utilization of proton pump inhibitors (PPI) has significantly increased worldwide. Parallel to the clinical benefits, potential long-term side effects have been observed, which, along with increasing ...
Mária Matuz, Ria Benkő, Zsófia Engi, Krisztina Schváb, Péter Doró, Réka Viola, Mária Szabó, Gyöngyvér Soós   +7 more
doaj   +1 more source

Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. [PDF]

PLoS ONE, 2018
BACKGROUND:Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease.
Hee Jeong Lee, Haekyung Lee, Song Hee Oh, Joonbyung Park, Suyeon Park, Jin Seok Jeon, HyunJin Noh, Dong Cheol Han, Soon Hyo Kwon   +8 more
doaj   +1 more source

The influence of proton pump inhibitors on tissue attachment around teeth and dental implants: A scoping review

Clinical and Experimental Dental Research, 2022
Objectives Proton pump inhibitors, such as omeprazole and pantoprazole, are frequently prescribed for the treatment of acid reflux. However, those medications have been shown to affect a variety of physiologic processes, including bone homeostasis and ...
Bhavneet K. Chawla, Robert E. Cohen, Elizabeth M. Stellrecht, Lisa M. Yerke   +3 more
doaj   +1 more source